Specific product information on COVID-19 vaccines available in the Yukon can be found in Section 8 of the Yukon Immunization Manual.

Fall 2023 NOVAVAX NUVAXOVID XBB.1.5 (Recombinant protein, Adjuvanted) COVID-19 Vaccine Recommendations			
Age	**Previous COVID-19 Vaccination History** (prior to COVID-19 XBB.1.5)	**Number of Doses of Nuvaxovid XBB,1.5 COVID-19 Vaccine**	**Recommended Interval Between Doses**
12 years of age and older	2 or more doses	1 dose	6 months after last dose
	1 dose	1 dose	8 weeks after last dose
	0 doses	2 doses	8 weeks between doses
Moderately to severely immunosuppressed (See Appendix A) **12 years of age and older**	3 or more doses	1 dose	6 months after last dose
	2 doses	1 dose	8 weeks after last dose
	1 dose	2 doses	8 weeks after last dose and between doses
	0 doses	3 doses	8 weeks between doses

Spring 2024 COVID-19 Vaccine Booster Eligibility ❶❷
Starting in the spring of 2024, the following individuals who are at increased risk of severe illness from COVID-19 may receive an additional dose of XBB.1.5 COVID-19 vaccine: • Adults 65 years of age and older • Adult residents of long term care homes and other congregate living settings for seniors • Individuals 6 months of age and older who are moderately to severely immunocompromised (see appendix A) due to underlying medical conditions or treatments
❶ If a high risk individual identified above has not recieved the dose(s) that they were eligible for in the fall of 2023, they should do so as soon as possible according to the fall 2023 schedule and reevaluate their COVID-19 vaccine eligibility in the fall of 2024. ❷ All other non-high risk individuals that have not recieved the dose(s) that they were eligible for in fall of 2023 should so as soon as possible and reevaluate their COVID-19 vaccine eligibility in the fall of 2024. Non-high risk individuals that have recieved their fall 2023 dose(s) are not recommended to recieve another booster dose in the spring of 2024, but may proceed with a booster after an informed discussion on the risks and benefits of vaccination provided that it has been 6 months since their last dose (minimum interval 5 months).

Preferred product:
For the fall 2023 and spring 2024 COVID-19 vaccine campaigns, Moderna XBB.1.5 is the primary immunizing agent. However, if clients have a contraindication to Moderna products, Pfizer XBB.1.5 should be offered. In those who are not able or willing to receive an mRNA COVID-19 vaccine, Novavax Nuvaxovid XBB.1.5 should be offered. Health care providers may vaccinate with Novavax Nuvaxovid XBB.1.5 if client expresses a preference and there are no contraindications.

Appendix A

Moderately to severely immunosuppressed includes:

- Active treatment for solid tumour or hematologic malignancies, or treatment for these conditions
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome) with associated humoral and/or cell-mediated immunodeficiency or immune dysregulation
- HIV with AIDS-defining illness or TB diagnosis in last 12 months before starting vaccine series, or severe immune compromise with CD4
- Active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (e.g., prednisone equivalent of ≥ 2 mg/kg/day or 20 mg/day if weight > 10 kg, for ≥ 14 days), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive (e.g., cancer chemotherapy, radiation therapy, cytotoxic drugs, calcineurin inhibitors, biological response modifiers and antibodies that target lymphocytes).
- Chronic kidney disease on dialysis